Thus, to investigate the expression of SLAMF7 on myeloma cells of EMD under therapeutic selection pressure, we screened our electronic database for patients with de novo EMD during elotuzumab treatment. This evidence concerns the gene SLAMF7 and plasma cell myeloma.